Abstract: The present invention provides ribosomal RNA origami nanostructures and in particular nanostructures comprising RNA staples, composition comprising such origami nanostructures as well as methods for manufacturing such origami structures.

Abstract: Provided herein are bispecific personalized aptamers that induce the cell death of cancer cells and methods of use thereof.

Abstract: Provided herein are aptamers that target cytotoxic T-lymphocyte and methods of use thereof.

Abstract: The present disclosure describes compositions and methods for selection functional aptamers. In certain embodiments, provided herein are methods of using aptamer cluster-containing particles to identify functional aptamers from an aptamer library. In certain embodiments, provided herein are functionally enriched populations of aptamers. In certain embodiments, provided herein are methods for selecting an aptamer for use in personalized cancer treatment and methods for preparing a tumor delivery system. In certain embodiments, provide herein are compositions comprise the aptamer cluster-containing particles, target cells (e.g., cancer cells, immune cells, etc.) and/or a detectable indicator of cellular function (e.g., a fluorescent indicator of apoptosis, cell proliferation, gene or protein expression, etc.).

Abstract: The present disclosure describes compositions and methods for rapid selection of both binding and functional oligonucleotides (DNA, RNA, or any natural or synthetic analog of these). In certain embodiments, provided herein are flow cells (e.g., flow cells for an Illumina sequencing instrument or a Polonator sequencing instrument) comprising within its flow chamber a plurality of immobilized aptamer clusters (e.g., from an aptamer library described herein) and, optionally, one or more target cells (e.g., cancer cells, immune cells, etc.) and/or a detectable indicator of cellular function (e.g., a fluorescent indicator of apoptosis, cell proliferation, gene or protein expression, etc.). In certain embodiments, provided herein are methods of using such an aptamer cluster-containing flow cell to identify functional aptamers from an aptamer library (e.g., in a sequencing instrument, such as an Illumina sequencing instrument).

Abstract: The present disclosure describes methods and compositions for the treatment of rapidly evolving biological entities (e.g., cancer cells, bacteria, virus, etc.) using therapeutic nucleic acids.

Abstract: The present disclosure describes compositions and methods for rapid selection of both binding and functional oligonucleotides (DNA, RNA, or any natural or synthetic analog of these). In certain embodiments, provided herein are flow cells (e.g., flow cells for an Illumina sequencing instrument or a Polonator sequencing instrument) comprising within its flow chamber a plurality of immobilized aptamer clusters (e.g., from an aptamer library described herein) and, optionally, one or more target cells (e.g., cancer cells, immune cells, etc.) and/or a detectable indicator of cellular function (e.g., a fluorescent indicator of apoptosis, cell proliferation, gene or protein expression, etc.). In certain embodiments, provided herein are methods of using such an aptamer cluster-containing flow cell to identify functional aptamers from an aptamer library (e.g., in a sequencing instrument, such as an Illumina sequencing instrument).

Abstract: The present disclosure describes compositions and methods for rapid selection of both binding and functional oligonucleotides (DNA, RNA, or any natural or synthetic analog of these). In certain embodiments, provided herein are flow cells (e.g., flow cells for an Illumina sequencing instrument or a Polonator sequencing instrument) comprising within its flow chamber a plurality of immobilized aptamer clusters (e.g., from an aptamer library described herein) and, optionally, one or more target cells (e.g., cancer cells, immune cells, etc.) and/or a detectable indicator of cellular function (e.g., a fluorescent indicator of apoptosis, cell proliferation, gene or protein expression, etc.). In certain embodiments, provided herein are methods of using such an aptamer cluster-containing flow cell to identify functional aptamers from an aptamer library (e.g., in a sequencing instrument, such as an Illumina sequencing instrument).

Abstract: The present invention provides ribosomal RNA origami nanostructures and in particular nanostructures comprising RNA staples, composition comprising such origami nanostructures as well as methods for manufacturing such origami structures.

Abstract: Nucleic acid origami devices are provided that are non-immunogenic and/or resistant to nucleases, which may be activated by one or more external cues, such as ligands, glucose concentration or electromagnetic fields; or used for attenuation or prevention of internalization of cell-surface receptors or prolongation of shelf-life of active agents. Further provided are methods for treating diabetes and methods for preparing the devices.

Abstract: Systems acting as logic gates and systems exhibiting quorum sensing are provided, wherein said systems comprise at least one effector nucleic acid origami device, at least one regulator nucleic acid origami device, at least one input and at least one output, and the nucleic acid origami devices are non-immunogenic and/or resistant to nucleases.

Abstract: The present disclosure describes compositions and methods for rapid selection of both binding and functional oligonucleotides (DNA, RNA, or any natural or synthetic analog of these). In certain embodiments, provided herein are flow cells (e.g., flow cells for an Illumina sequencing instrument or a Polonator sequencing instrument) comprising within its flow chamber a plurality of immobilized aptamer clusters (e.g., from an aptamer library described herein) and, optionally, one or more target cells (e.g., cancer cells, immune cells, etc.) and/or a detectable indicator of cellular function (e.g., a fluorescent indicator of apoptosis, cell proliferation, gene or protein expression, etc.). In certain embodiments, provided herein are methods of using such an aptamer cluster-containing flow cell to identify functional aptamers from an aptamer library (e.g., in a sequencing instrument, such as an Illumina sequencing instrument).

Abstract: Dipeptide analogs comprising a tryptophan (Trp) moiety coupled to a beta-sheet breaker moiety derived from alpha-aminoisobutyric acid (Aib) are disclosed. The dipeptide analogs exhibit an improved performance in inhibiting amyloid fibril formation, as compared to previously described dipeptides. Compositions containing the dipetide analogs and uses thereof in treating amyloid-associated diseases and disorders are also disclosed.

Abstract: Systems acting as logic gates and systems exhibiting quorum sensing are provided, wherein said systems comprise at least one effector nucleic acid origami device, at least one regulator nucleic acid origami device, at least one input and at least one output, and the nucleic acid origami devices are non-immunogenic and/or resistant to nucleases.

Abstract: Nucleic acid origami devices are provided that are non-immunogenic and/or resistant to nucleases, which may be activated by one or more external cues, such as ligands, glucose concentration or electromagnetic fields; or used for attenuation or prevention of internalization of cell-surface receptors or prolongation of shelf-life of active agents. Further provided are methods for treating diabetes and methods for preparing the devices.

Abstract: Dipeptide analogs comprising a tryptophan (Trp) moiety coupled to a beta-sheet breaker moiety derived from alpha-aminoisobutyric acid (Aib) are disclosed. The dipeptide analogs exhibit an improved performance in inhibiting amyloid fibril formation, as compared to previously described dipeptides. Compositions containing the dipetide analogs and uses thereof in treating amyloid-associated diseases and disorders are also disclosed.

Abstract: Dipeptide analogs comprising a tryptophan (Trp) moiety coupled to a beta-sheet breaker moiety derived from alpha-aminoisobutyric acid (Aib) are disclosed. The dipeptide analogs exhibit an improved performance in inhibiting amyloid fibril formation, as compared to previously described dipeptides. Compositions containing the dipeptide analogs and uses thereof in treating amyloid-associated diseases and disorders are also disclosed.

Abstract: Dipeptide analogs comprising a tryptophan (Trp) moiety coupled to a beta-sheet breaker moiety derived from alpha-aminoisobutyric acid (Aib) are disclosed. The dipeptide analogs exhibit an improved performance in inhibiting amyloid fibril formation, as compared to previously described dipeptides. Compositions containing the dipeptide analogs and uses thereof in treating amyloid-associated diseases and disorders are also disclosed.